Drug products: Cortimyk, Daktacort®, Fenuril®-Hydrokortison, Ficortril®, Fucidin®-Hydrocortison, Fucidin-Hydrocortison, Fusidinsyra/Hydrokortison 2care4, Hydrokortison Apofri, Hydrokortison Evolan, Hydrokortison PharmSwed, Hydrokortison-svavel i Essex kräm APL, Locoid, Locoid Crelo, Locoid Lipid, Locoid®, Mildison Lipid, Softacort, Terracortril med polymyxin B, Terracortril med Polymyxin B, Terra-Cortril med polymyxin B, Terracortril®, Terracortril® med Polymyxin B, Uniderm®, Xerclear, Zoviduo
ATC code: D01AC20, D06BB53, D07AA02, D07AB02, D07CA01, D07XA01, S01BA02, S03CA04
Published controlled studies on differences between men and women regarding efficacy, safety and pharmacokinetics of topical hydrocortisone are lacking.
No studies with a clinical relevant sex analysis regarding the pharmacokinetics or dosing of topical hydrocortisone have been found.
No studies with a clinical relevant sex analysis regarding the effects of topical hydrocortisone have been found.
No studies with a clinical relevant sex analysis regarding the adverse effects of topical hydrocortisone have been found.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
A retrospective analysis of patients with eczema or psoriasis on standard dermatological treatment (295 men, 291 women) found that significantly more men than women (79; 63%, 47; 37%) were administered whole-body UV treatment. Also, the results indicated that men had more treatments appointments per individual than women. Women were prescribed more emollients than men .
Date of litterature search: 2022-06-29
Reviewed by: Diana Rydberg
Approved by: Karin Schenck-Gustafsson